 By M. Marin NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Contract Validates Potential of HemoDefend Technology Cytosorbents NASDAQ:CTSO was awarded a Defense Health Agency Small Business Technology Transfer STTR Phase III contract valued at up to 2.9 million over a two-year period, enabling CTSO to move HemoDefend-BGA closer to commercialization. We believe the new contract validates the 